

Myron E Schwartz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6756613/publications.pdf>

Version: 2024-02-01

277
papers

39,622
citations

7087

78
h-index

2680

193
g-index

279
all docs

279
docs citations

279
times ranked

30509
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
2	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , 2009, 10, 35-43.	5.1	1,920
3	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863
4	Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 698-711.	3.0	1,545
5	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	13.9	1,148
6	Resection and Liver Transplantation for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 181-200.	1.8	1,043
7	Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
8	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
9	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	3.6	632
10	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.4	589
11	Recurrence of Hepatocellular Cancer After Resection. <i>Annals of Surgery</i> , 2015, 261, 947-955.	2.1	576
12	A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 850-855.	0.6	517
13	The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies. <i>Cancer Research</i> , 2009, 69, 2514-2522.	0.4	493
14	Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. <i>Liver Transplantation</i> , 2004, 10, 534-540.	1.3	403
15	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	0.6	389
16	Long-Term Results With Multimodal Adjuvant Therapy and Liver Transplantation for the Treatment of Hepatocellular Carcinomas Larger Than 5 Centimeters. <i>Annals of Surgery</i> , 2002, 235, 533-539.	2.1	368
17	Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. <i>Hepatology</i> , 1995, 21, 30-34.	3.6	353
18	Resection of hepatocellular cancer ≥ 2 cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326

#	ARTICLE	IF	CITATIONS
19	The role of hepatic resection in the treatment of hepatocellular cancer. <i>Hepatology</i> , 2015, 62, 440-451.	3.6	310
20	One Hundred Nine Living Donor Liver Transplants in Adults and Children: A Single-Center Experience. <i>Annals of Surgery</i> , 2001, 234, 301-312.	2.1	289
21	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	7.0	278
22	Strategies for the management of hepatocellular carcinoma. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 424-432.	4.3	253
23	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	3.2	251
24	Liver Transplantation: the Preferred Treatment for Early Hepatocellular Carcinoma in the Setting of Cirrhosis?. <i>Annals of Surgical Oncology</i> , 2007, 14, 548-552.	0.7	250
25	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	0.7	249
26	LONG-TERM MEDICAL COMPLICATIONS IN PATIENTS SURVIVING 5 YEARS AFTER LIVER TRANSPLANT. <i>Transplantation</i> , 2000, 69, 781-789.	0.5	245
27	Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. <i>Lancet Oncology</i> , The, 2002, 3, 593-603.	5.1	242
28	USE OF LIVERS WITH MICROVESICULAR FAT SAFELY EXPANDS THE DONOR POOL. <i>Transplantation</i> , 1997, 64, 248-251.	0.5	242
29	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	5.8	240
30	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
31	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
32	The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , 1998, 28, 831-838.	3.6	212
33	BILIARY COMPLICATIONS IN 96 CONSECUTIVE RIGHT LOBE LIVING DONOR TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2004, 77, 1842-1848.	0.5	212
34	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	1.8	211
35	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	1.8	206
36	Treatment of ischemia due to "steal" by arteriovenous fistula with distal artery ligation and revascularization. <i>Journal of Vascular Surgery</i> , 1988, 7, 770-773.	0.6	196

#	ARTICLE	IF	CITATIONS
37	Central nervous system complications in liver transplant recipients - incidence, timing, and long-term follow-up. <i>Clinical Transplantation</i> , 2000, 14, 1-7.	0.8	192
38	Adult Living Donor Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 142-149.	2.1	185
39	Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. <i>American Journal of Gastroenterology</i> , 2000, 95, 1535-1538.	0.2	166
40	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.2	165
41	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
42	SAFE USE OF HEPATIC ALLOGRAFTS FROM DONORS OLDER THAN 70 YEARS ¹ . <i>Transplantation</i> , 1996, 62, 62-65.	0.5	159
43	Liver Transplantation for Autoimmune Hepatitis. <i>Hepatology</i> , 2000, 32, 693-700.	3.6	155
44	Anatomic variations in right liver living donors ¹ ¹ No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2004, 198, 577-582.	0.2	148
45	Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis. <i>Hepatology</i> , 1992, 16, 949-955.	3.6	143
46	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1047-1052.	3.6	142
47	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
48	Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease*. <i>Clinical Transplantation</i> , 2004, 18, 94-99.	0.8	134
49	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	1.8	133
50	Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1 α -mediated stellate cell activation. <i>Hepatology</i> , 2009, 49, 2055-2067.	3.6	132
51	Quality of life after lobectomy for adult liver transplantation ¹ . <i>Transplantation</i> , 2002, 73, 1593-1597.	0.5	127
52	SELECTIVE REVASCULARIZATION OF HEPATIC ARTERY THROMBOSES AFTER LIVER TRANSPLANTATION IMPROVES PATIENT AND GRAFT SURVIVAL ¹ . <i>Transplantation</i> , 1997, 64, 1295-1299.	0.5	127
53	Aggressive Surgical Treatment of Intrahepatic Cholangiocarcinoma: Predictors of Outcomes. <i>Journal of the American College of Surgeons</i> , 1998, 187, 365-372.	0.2	125
54	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002â€“2020). <i>Gastroenterology</i> , 2021, 161, 879-898.	0.6	123

#	ARTICLE	IF	CITATIONS
55	Higher Incidence of Diabetes in Liver Transplant Recipients With Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 1998, 26, 30-33.	1.1	123
56	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 1222-1231.	1.8	121
57	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
58	Liver transplantation for neuroendocrine tumors. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 208-212.	0.9	120
59	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017, 66, 952-961.	1.8	120
60	ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON'S DISEASE. <i>Transplantation</i> , 2001, 72, 1232-1236.	0.5	114
61	Utility of Lens culinaris Agglutinin-Reactive Fraction of α_2 -Fetoprotein and Des-Gamma-Carboxy Prothrombin, Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 104-113.	2.4	113
62	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
63	ACCURACY AND SIGNIFICANCE OF COMPLETED TOMOGRAPHIC SCAN ASSESSMENT OF HEPATIC VOLUME IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 545-550.	0.5	109
64	Advances in resection and transplantation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 262-276.	1.8	107
65	Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. <i>Hepatology</i> , 2015, 61, 895-904.	3.6	105
66	Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 583-593.	1.8	105
67	Intratumoral Adenovirus-Mediated Suicide Gene Transfer for Hepatic Metastases from Colorectal Adenocarcinoma: Results of a Phase I Clinical Trial. <i>Molecular Therapy</i> , 2001, 4, 182-191.	3.7	104
68	Comparison of Surgical Outcomes for Hepatocellular Carcinoma in Patients With Hepatitis B Versus Hepatitis C: A Western Experience. <i>Annals of Surgical Oncology</i> , 2000, 7, 764-770.	0.7	101
69	Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4073-4085.	3.2	97
70	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 3759-3769.	2.3	97
71	Liver Resection Under Total Vascular Isolation Variations on a Theme. <i>Annals of Surgery</i> , 1993, 217, 15-19.	2.1	94
72	Retransplantation for late liver graft failure: Predictors of mortality. <i>Liver Transplantation</i> , 2000, 6, 174-179.	1.3	94

#	ARTICLE	IF	CITATIONS
73	EFFICACY OF TACROLIMUS AS RESCUE THERAPY FOR CHRONIC REJECTION IN ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 64, 258-263.	0.5	92
74	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	6.1	90
75	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
76	Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. <i>American Journal of Surgery</i> , 2008, 196, 160-169.	0.9	87
77	Is it Time to Abandon the Milan Criteria?. <i>Annals of Surgery</i> , 2018, 268, 690-699.	2.1	87
78	N-ACETYLCYSTEINE AMELIORATES REPERFUSION INJURY AFTER WARM HEPATIC ISCHEMIA. <i>Transplantation</i> , 1995, 59, 6-9.	0.5	82
79	Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers. <i>Journal of Hepatology</i> , 2008, 49, 581-588.	1.8	80
80	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 219-229.	3.7	79
81	Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. <i>Cancer Medicine</i> , 2020, 9, 4962-4970.	1.3	78
82	Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 650-658.	2.1	77
83	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 140-151.	2.6	77
84	Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 102-107.	0.9	75
85	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	1.8	75
86	Wound complications after in situ bypass. <i>Journal of Vascular Surgery</i> , 1988, 7, 802-807.	0.6	74
87	Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 3888-3899.	3.9	74
88	Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?. <i>Annals of Surgical Oncology</i> , 2009, 16, 379-384.	0.7	73
89	Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. <i>Annals of Surgery</i> , 2021, 274, 780-788.	2.1	72
90	Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. <i>Targeted Oncology</i> , 2014, 9, 145-153.	1.7	70

#	ARTICLE	IF	CITATIONS
91	How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. <i>Journal of Hepatology</i> , 2005, 43, 584-589.	1.8	69
92	Resection of Hepatocellular Carcinoma with Macroscopic Vascular Invasion. <i>Annals of Surgical Oncology</i> , 2013, 20, 3754-3760.	0.7	69
93	PD-1 inhibitor as bridge therapy to liver transplantation?. <i>American Journal of Transplantation</i> , 2021, 21, 1979-1980.	2.6	69
94	Living related liver transplantation for acute liver failure in children. <i>Liver Transplantation</i> , 1999, 5, 161-165.	1.9	68
95	PROLONGED PRESERVATION IN UNIVERSITY OF WISCONSIN SOLUTION ASSOCIATED WITH HEPATIC ARTERY THROMBOSIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1993, 56, 1399-1402.	0.5	65
96	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	1.8	64
97	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64
98	Current management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 10223.	1.4	61
99	Outcomes following resection of intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2015, 17, 344-351.	0.1	60
100	Transplant Recipients Seletion: Peacetime vs. Wartime Triage. <i>Cambridge Quarterly of Healthcare Ethics</i> , 1992, 1, 327-331.	0.5	59
101	Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases. <i>PLoS ONE</i> , 2012, 7, e36979.	1.1	59
102	Second hepatic resection for recurrent hepatocellular cancer: A Western experience. <i>Journal of Hepatology</i> , 2011, 55, 346-350.	1.8	58
103	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	6.1	57
104	An Integrated Approach to Intestinal Failure. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 554-562.	0.9	55
105	Hepatic Resection for Primary Hepatolithiasis: A Single-Center Western Experience. <i>Journal of the American College of Surgeons</i> , 2012, 215, 622-626.	0.2	55
106	Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of Post Administration ALT Elevation. <i>American Journal of Transplantation</i> , 2004, 4, 1805-1809.	2.6	54
107	SUCCESSFUL USE OF AN ENHANCED IMMUNOSUPPRESSIVE PROTOCOL WITH PLASMAPHERESIS FOR ABO-INCOMPATIBLE MISMATCHED GRAFTS IN LIVER TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 986-990.	0.5	53
108	Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2002, 9, 237-241.	2.0	52

#	ARTICLE	IF	CITATIONS
109	Resection of Hepatocellular Carcinoma Without Cirrhosis. <i>Annals of Surgery</i> , 2012, 255, 1135-1143.	2.1	52
110	LIVER TRANSPLANTATION IN A PATIENT WITH ACUTE LIVER FAILURE DUE TO SICKLE CELL INTRAHEPATIC CHOLESTASIS. <i>Transplantation</i> , 2000, 69, 675-677.	0.5	52
111	Expression of p53 and PCNA in Cholangiocarcinoma and Primary Sclerosing Cholangitis. <i>Modern Pathology</i> , 2000, 13, 1265-1268.	2.9	51
112	Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. <i>Hepatology</i> , 2005, 42, 1420-1428.	3.6	45
113	Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. <i>European Radiology</i> , 2020, 30, 1020-1030.	2.3	45
114	Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 812-821.e2.	0.2	44
115	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
116	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021, 74, 183-199.	3.6	42
117	Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. <i>Gut</i> , 2023, 72, 736-748.	6.1	42
118	Marked Differences in Acute Cellular Rejection Rates between Living-Donor and Deceased-Donor Liver Transplant Recipients. <i>Transplantation</i> , 2005, 80, 1072-1080.	0.5	41
119	Prognostic Significance of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2015, 101, 58-65.	1.2	40
120	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
121	Trefoil factor-3 expression in human colon cancer liver metastasis. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 143-151.	1.7	38
122	Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1083-1090.	1.5	38
123	Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. <i>Transplant International</i> , 2000, 13, 73-78.	0.8	38
124	The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation1. <i>Clinical Transplantation</i> , 2004, 18, 152-155.	0.8	37
125	SAFE TRANSPLANTATION OF BLOOD TYPE A2 LIVERS TO BLOOD TYPE O RECIPIENTS1. <i>Transplantation</i> , 1999, 67, 1071-1073.	0.5	37
126	Cholangiolocellular Carcinoma: An Innocent-Looking Malignant Liver Tumor Mimicking Ductular Reaction. <i>Seminars in Liver Disease</i> , 2011, 31, 104-110.	1.8	36

#	ARTICLE	IF	CITATIONS
127	Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. <i>Hepatology</i> , 1995, 21, 30-34.	3.6	36
128	Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon- α 2a upon Progression. <i>Oncologist</i> , 2005, 10, 718-727.	1.9	35
129	Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. <i>Hpb</i> , 2020, 22, 677-689.	0.1	35
130	Actual 10-year survival following hepatectomy for hepatocellular carcinoma. <i>Hpb</i> , 2014, 16, 830-835.	0.1	34
131	OBVIATION OF PREREPERFUSION RINSING AND DECREASE IN PRESERVATION/REPERFUSION INJURY IN LIVER TRANSPLANTATION BY PORTAL BLOOD FLUSHING ¹ . <i>Transplantation</i> , 1994, 57, 799-802.	0.5	33
132	Disentangling the effects of race and socioeconomic factors on liver transplantation rates for hepatocellular carcinoma. <i>Clinical Transplantation</i> , 2016, 30, 714-721.	0.8	33
133	Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. <i>American Journal of Transplantation</i> , 2020, 20, 220-230.	2.6	33
134	Reporting and methodological qualities of published surgical meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 4-16.	2.4	32
135	Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 1497-1504.	0.1	30
136	Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There. <i>Seminars in Liver Disease</i> , 2006, 26, 248-253.	1.8	29
137	The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. <i>Transplant International</i> , 2011, 24, 243-250.	0.8	28
138	Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: A multicenter study. <i>Surgery</i> , 2019, 165, 516-524.	1.0	28
139	Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1729-1738.e1.	0.2	27
140	THE ARCUATE LIGAMENT SYNDROME IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1993, 56, 223.	0.5	25
141	FK506 VERSUS CYCLOSPORINE AS PRIMARY IMMUNOSUPPRESSIVE AGENT FOR ORTHOTOPIC LIVER ALLOGRAFT RECIPIENTS HISTOLOGIC AND IMMUNOPATHOLOGIC OBSERVATIONS ¹ . <i>Transplantation</i> , 1993, 56, 1389-1393.	0.5	25
142	Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Liver Cancer</i> , 2020, 9, 138-147.	4.2	25
143	Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). <i>Gastrointestinal Endoscopy</i> , 2012, 76, 293-300.	0.5	24
144	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2022, 71, 2069-2080.	6.1	24

#	ARTICLE	IF	CITATIONS
145	Detection of Hepatitis B and Hepatitis C Viral Sequences in Fulminant Hepatic Failure of Unknown Etiology. <i>American Journal of Clinical Pathology</i> , 1995, 104, 588-593.	0.4	23
146	Epstein-Barr virus and human hepatocellular carcinoma. <i>Cancer Letters</i> , 2003, 192, 49-57.	3.2	23
147	Carcinoma Ex Microcystic Adenoma of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 305-310.	2.1	23
148	Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. <i>Cancer Imaging</i> , 2020, 20, 43.	1.2	23
149	Angiomyolipoma of the liver: immunohistochemical study of a case. <i>Liver</i> , 1991, 11, 158-161.	0.1	22
150	Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. <i>Cardiovascular Pathology</i> , 2009, 18, 243-246.	0.7	22
151	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 734-740.	0.6	22
152	Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. <i>Journal of the American College of Surgeons</i> , 2003, 197, 765-769.	0.2	21
153	Diaphragmatic Hernia After Hepatic Resection: Case Series at a Single Western Institution. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1910-1914.	0.9	21
154	Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 805-811.	0.4	21
155	Outcomes of resection for solitary $\leq 5\text{ cm}$ intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2018, 163, 698-702.	1.0	21
156	Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. <i>Liver Transplantation</i> , 2020, 26, 888-898.	1.3	21
157	N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes. <i>Molecular Cancer Research</i> , 2021, 19, 1868-1877.	1.5	21
158	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	5.8	21
159	Assessment of Liver Allograft Function by Hyaluronic Acid and Endothelin Levels. <i>Journal of Surgical Research</i> , 1997, 73, 123-128.	0.8	20
160	Treatment Strategies for Hepatocellular Carcinoma in Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 401-411.	0.9	20
161	Resection or transplant listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. <i>Hpb</i> , 2013, 15, 134-141.	0.1	20
162	Primary Hepatocellular Carcinoma: Transplant Versus Resection. <i>Seminars in Liver Disease</i> , 1994, 14, 135-139.	1.8	19

#	ARTICLE	IF	CITATIONS
163	Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. <i>American Journal of Gastroenterology</i> , 1998, 93, 2148-2153.	0.2	19
164	De Novo Hepatocellular Carcinoma Occurring in a Transplanted Liver: Case Report and Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1780-1782.	1.1	19
165	Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study. <i>American Journal of Surgery</i> , 2018, 215, 125-130.	0.9	19
166	Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 122-132.	2.0	19
167	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. <i>Clinical Cancer Research</i> , 2022, 28, 3443-3451.	3.2	19
168	Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein. <i>Liver</i> , 1995, 15, 30-34.	0.1	18
169	Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas. <i>Liver International</i> , 2010, 30, 996-1002.	1.9	18
170	Liver Transplantation for Liver Rupture Due to Light Chain Deposition Disease: A Case Report. <i>Seminars in Liver Disease</i> , 2006, 26, 298-303.	1.8	17
171	Comparison of Patterns and Outcomes of Liver Resection for Hepatocellular Carcinoma: East vs West. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1972-1974.	2.4	17
172	Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 161-168.	0.7	17
173	Persistent Hypersplenism Early After Liver Transplant. <i>Transplantation</i> , 1997, 64, 1481-1483.	0.5	17
174	Unresectable Squamous Cell Carcinoma of Donor Origin Treated With Immunosuppression Withdrawal and Liver Replantation. <i>American Journal of Transplantation</i> , 2004, 4, 278-282.	2.6	16
175	Effluent levels of thrombomodulin predict early graft function in clinical liver transplantation. <i>Liver</i> , 1997, 17, 224-229.	0.1	16
176	HIV infection modulates IL-1 β response to LPS stimulation through a TLR4-NLRP3 pathway in human liver macrophages. <i>Journal of Leukocyte Biology</i> , 2019, 105, 783-795.	1.5	16
177	New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. <i>BioDrugs</i> , 1997, 8, 469-488.	2.2	15
178	Primary Hepatic Signet Ring Cell Neuroendocrine Tumor: A Case Report with Literature Review. <i>Seminars in Liver Disease</i> , 2010, 30, 422-428.	1.8	15
179	Prognostic Clinicopathologic Factors in Longitudinally Followed Patients With Metastatic Small Bowel Carcinoid Tumors. <i>Pancreas</i> , 2011, 40, 1253-1257.	0.5	15
180	Assessment of Hepatocellular Carcinoma Response to ^{90}Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. <i>Radiology Imaging Cancer</i> , 2020, 2, e190094.	0.7	15

#	ARTICLE	IF	CITATIONS
181	Modern management of splenomegaly in patients with myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 1441-1451.	0.8	15
182	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15
183	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021, 17, e1009589.	1.5	15
184	Arteriovenous Fistula Following Punch-Graft Hair Transplantation. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1989, 15, 754-755.	0.8	14
185	A 42-Year-Old Woman with Liver Masses and Long-Term Use of Oral Contraceptives. <i>Seminars in Liver Disease</i> , 1999, 19, 339-344.	1.8	14
186	Invasive Colloid Carcinoma Arising from Intraductal Papillary Neoplasm in a 50-Year-Old Woman with Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2004, 24, 209-213.	1.8	14
187	Management of Hepatic Adenoma in Glycogen Storage Disease Ia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1995, 20, 225-228.	0.9	13
188	Use of intraoperative Doppler ultrasound to diagnose hepatic venous obstruction in a right lobe living donor liver transplant. <i>Liver Transplantation</i> , 2001, 7, 547-550.	1.3	13
189	Post-traumatic pseudoaneurysm of the common hepatic artery with duodenal fistula. <i>Hpb</i> , 2002, 4, 183-186.	0.1	13
190	Hepatocellular carcinoma in long-term oral contraceptive use. <i>Liver</i> , 1996, 16, 372-376.	0.1	13
191	Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 920-926.	0.2	13
192	Loss of speech after orthotopic liver transplantation. <i>Transplant International</i> , 1995, 8, 234-237.	0.8	13
193	Adult-to-adult living donor liver transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 303-312.	0.9	12
194	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	15.2	12
195	Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients. <i>Mediators of Inflammation</i> , 2000, 9, 141-146.	1.4	11
196	Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. <i>Frontiers in Oncology</i> , 2018, 8, 220.	1.3	11
197	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. <i>Abdominal Radiology</i> , 2022, 47, 969-980.	1.0	11
198	Correlation between von Willebrand factor levels and early graft function in clinical liver transplantation. <i>Clinical Transplantation</i> , 1999, 13, 25-31.	0.8	10

#	ARTICLE	IF	CITATIONS
199	Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e133-e137.	0.2	10
200	Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 940-947.e3.	0.6	10
201	Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 571-581.	1.8	10
202	RESISTANT HEPATIC ALLOGRAFT REJECTION SUCCESSFULLY TREATED WITH CYCLOPHOSPHAMIDE AND PLASMAPHERESIS. <i>Transplantation</i> , 1990, 50, 702-703.	0.5	9
203	EVIDENCE THAT THE SYSTEMATIC ANALYSIS OF BILE CYTOLOGY PERMITS MONITORING OF HEPATIC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1992, 54, 471-474.	0.5	9
204	Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 630-631.	4.3	9
205	Multiple Inflammatory and Serum Amyloid A Positive Telangiectatic Hepatic Adenomas with Glycogenated Nuclei Arising in a Background of Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2008, 28, 434-439.	1.8	9
206	Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1630-1638.	0.2	9
207	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100364.	2.6	9
208	BACKTABLE RESECTION OF A GIANT CAVERNOUS HEMANGIOMA IN A DONOR LIVER. <i>Transplantation</i> , 1995, 60, 616.	0.5	8
209	Closure of an iatrogenic gastrogastric fistula created during EUS-directed transgastric ERCP. <i>VideoGIE</i> , 2016, 1, 61-62.	0.3	8
210	Abdominal Tuberculosis Mimicking Cancer Clinically and on Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Imaging: A Two-Case Series. <i>American Journal of Case Reports</i> , 2020, 21, e918901.	0.3	8
211	Use of the superficial femoral vein as a replacement for large veins. <i>Journal of Vascular Surgery</i> , 1991, 13, 460-461.	0.6	7
212	Surgical management of noncirrhotic portal hypertension. <i>Clinical Liver Disease</i> , 2015, 5, 112-115.	1.0	7
213	Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. <i>Clinical Imaging</i> , 2016, 40, 897-901.	0.8	7
214	Transmission of factor VII deficiency through liver transplantation. <i>Transplant International</i> , 1999, 12, 278-280.	0.8	7
215	The role of fibrin sealants in hepatic surgery. <i>Surgical Technology International</i> , 2007, 16, 31-6.	0.1	7
216	Postoperative intussusception after vaginal vault suspension. <i>American Journal of Obstetrics and Gynecology</i> , 1986, 154, 633-634.	0.7	6

#	ARTICLE	IF	CITATIONS
217	CRITICAL GRAFT SIZE IN ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION: THE IMPACT OF THE RECIPIENT'S DISEASE.. Transplantation, 2000, 69, S290.	0.5	6
218	Histological Changes in Nontumoral Liver Secondary to Radioembolization of Hepatocellular Carcinoma with Yttrium 90-impregnated Microspheres: Report of Two Cases. Seminars in Liver Disease, 2014, 34, 465-468.	1.8	6
219	At Diagnosis of Hepatocellular Carcinoma, African Americans With Hepatitis C Have Better Liver Function Than Other Patients. Clinical Liver Disease, 2018, 12, 109-112.	1.0	6
220	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Modern Pathology, 2021, 34, 823-833.	2.9	6
221	Early effect of 90Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. European Radiology, 2021, 31, 5791-5801.	2.3	6
222	Surgical Resection for Hepatocellular Carcinoma in the Noncirrhotic: The Western Experience. Recent Results in Cancer Research, 2013, 190, 85-100.	1.8	6
223	Candidate selection criteria for living donor liver transplantation. Mount Sinai Journal of Medicine, 2003, 70, 171-3.	1.9	6
224	Renal cell carcinoma with inferior vena cava thrombus extending to the right atrium diagnosed during pregnancy. Therapeutic Advances in Urology, 2017, 9, 155-159.	0.9	5
225	A novel online calculator to predict perioperative blood transfusion in patients undergoing liver resection for hepatocellular carcinoma: an international multicenter study. Hpb, 2020, 22, 1711-1721.	0.1	5
226	Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. European Radiology, 2022, 32, 6493-6503.	2.3	5
227	DIABETOGENICITY OF FK506 VERSUS CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS. Transplantation, 1994, 58, 370-371.	0.5	5
228	IFN γ secretion following stimulation with total tumor peptides from autologous human tumors. Journal of Immunological Methods, 2000, 241, 61-68.	0.6	4
229	Metzenbaum-Assisted Liver Resection: A Safe and Effective Liver Resection Technique. Digestive Surgery, 2014, 31, 312-317.	0.6	4
230	Intrathecal Morphine Administration Does Not Affect Survival After Liver Resection for Hepatocellular Carcinoma. Seminars in Cardiothoracic and Vascular Anesthesia, 2019, 23, 309-318.	0.4	4
231	Outcomes of liver transplantation for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hpb, 2022, 24, 470-477.	0.1	4
232	A 67-Year-Old Man with Hepatitis C Virus Infection and a Liver Tumor. Seminars in Liver Disease, 2000, 20, 227-232.	1.8	4
233	The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncologica, 2020, 59, 940-943.	0.8	4
234	Recurrent giant hemangiomas of liver: Report of two rare cases with literature review. World Journal of Gastrointestinal Surgery, 2012, 4, 262.	0.8	4

#	ARTICLE	IF	CITATIONS
235	LIVER TRANSPLANTATION IN A PATIENT WITH HIGH COLD AGGLUTININ TITERS. <i>Transplantation</i> , 1995, 60, 622-623.	0.5	3
236	Functional abdominal complaints occurred frequently in living liver donors after donation. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 611-615.	0.6	3
237	Expanded Criteria for Resection: Are Current Guidelines Too Conservative?. <i>Current Hepatology Reports</i> , 2016, 15, 323-326.	0.4	3
238	Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. <i>Cancer Research</i> , 2021, 81, CT182-CT182.	0.4	3
239	High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation. <i>Transplant International</i> , 1995, 8, 152-156.	0.8	3
240	Donor des-gamma-carboxy prothrombin positivity is a risk factor for poor early graft function in liver transplantation. <i>Transplant International</i> , 1998, 11, 143-146.	0.8	3
241	Giant hemangioma of the adrenal. <i>Israel Medical Association Journal</i> , 2004, 6, 705-6.	0.1	3
242	Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores. <i>Anticancer Research</i> , 2016, 36, 399-402.	0.5	3
243	Endoscopic color Doppler assessment of portal and hepatic vasculature after orthotopic liver transplantation. <i>Gastrointestinal Endoscopy</i> , 1991, 37, 190-191.	0.5	2
244	Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage Oâ€œB1 Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2015, 110, 595.	0.2	2
245	Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. <i>Pancreas</i> , 2016, 45, 528-532.	0.5	2
246	Perioperative Management in Hepatic Resections: Comparative Effectiveness of Neuraxial Anesthesia and Disparity of Care Patterns. <i>Anesthesia and Analgesia</i> , 2018, 127, 855-863.	1.1	2
247	Outcomes After Differing Surgical Strategies in Patients With Small Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, e50-e51.	0.5	2
248	Left lateral segment pediatric liver transplantation: a 25 year experience at Mount Sinai. <i>Hpb</i> , 2022, 24, 817-824.	0.1	2
249	Surgical resection for advanced gallbladder carcinoma. The Mount Sinai experience. <i>Hepato-Gastroenterology</i> , 2010, 57, 1005-12.	0.5	2
250	REVERSAL OF SEVERE FK506 SIDE EFFECTS BY CONVERSION TO CYCLOSPORINE-BASED IMMUNOSUPPRESSION. <i>Transplantation</i> , 1994, 58, 380-381.	0.5	2
251	Perspective: Incision revision. <i>Nature</i> , 2014, 516, S17-S17.	13.7	1
252	Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohnâ€™s Disease: A 9-Year Survival. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	1

#	ARTICLE	IF	CITATIONS
253	Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. <i>Hepatology International</i> , 2021, 15, 459-471.	1.9	1
254	Abstract 64: Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, , .		1
255	INCREASED RISK OF EARLY REJECTION CORRELATES WITH RECOVERY OF CD3 CELL COUNT AFTER LIVER TRANSPLANT IN PATIENTS RECEIVING OKT3 INDUCTION1. <i>Transplantation</i> , 1997, 64, 1214-1216.	0.5	1
256	Therapeutic Alternatives in Primary Aortic Salmonellosisâ€”A Case Report. <i>Vascular Surgery</i> , 1989, 23, 485-490.	0.3	0
257	Early Graft-Sigmoid Erosion in a Patient with Prior Sigmoid Resectionâ€”A Case Report. <i>Vascular Surgery</i> , 1993, 27, 240-241.	0.3	0
258	INTESTINAL TRANSPLANTATION WITH LYMPHOCYTOXIC CROSSMATCHING.. <i>Transplantation</i> , 2000, 69, S184.	0.5	0
259	Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin. <i>Journal of the American College of Surgeons</i> , 2007, 205, S93-S94.	0.2	0
260	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	3.6	0
261	Perioperative Blood Transfusion and Long-Term Outcomes After Resection of Hilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1192-1193.	0.9	0
262	Transplantation for hepatocellular carcinoma: More haste, less speed?. <i>Hepatology</i> , 2015, 62, 1327-1328.	3.6	0
263	917 Taking the EDGE off. <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB184-AB185.	0.5	0
264	Idiopathic perinatal hepatic infarct as a cause of liver mass. <i>Annals of Pediatric Surgery</i> , 2016, 12, 167-169.	0.1	0
265	Reply to â€œAssociation of blood transfusion during resection for hepatocellular carcinoma with postoperative recurrence and overall survival: A cautionary commentâ€• <i>Journal of Hepatology</i> , 2016, 65, 229-230.	1.8	0
266	Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohnâ€™s Disease: A Case with Prolonged Survival. <i>American Journal of Gastroenterology</i> , 2018, 113, S1176-S1177.	0.2	0
267	Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 367-374.	0.6	0
268	Surgery for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: The cornerstone but not the only stone. <i>American Journal of Surgery</i> , 2019, 217, 192.	0.9	0
269	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. <i>Journal of Hepatology</i> , 2020, 73, S28-S29.	1.8	0
270	Inpatient Palliative Care Consultation Is Associated with Lower Hazard of Readmission for Patients with Hepatocellular Carcinoma (RP506). <i>Journal of Pain and Symptom Management</i> , 2020, 60, 231-232.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression. <i>Blood</i> , 2014, 124, 1871-1871.	0.6	0
272	Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, e15644-e15644.	0.8	0
273	Von Meyenburg complexes: a rare intrahepatic bile duct malformation. <i>Minerva Surgery</i> , 2020, 75, 272-274.	0.1	0
274	685â€¦Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma. , 2021, 9, A713-A713.		0
275	Unusual venous thrombosis associated with protein C deficiency. <i>Journal of Vascular Surgery</i> , 1988, 7, 443-445.	0.6	0
276	ACUTE HEPATIC FAILURE IN SEVEN PATIENTS AFTER PROPHYLAXIS AND THERAPY WITH ANTITUBERCULOUS AGENTS. <i>Transplantation</i> , 1994, 58, 372-376.	0.5	0
277	Neoadjuvant immunotherapy for resectable hepatocellular carcinoma â€“ Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 505.	3.7	0